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Edited by Amy McGoughAbstract Major sites for Rho-kinase on the myosin phospha-
tase target subunit (MYPT1) are Thr695 and Thr850. Phos-
phorylation of Thr695 inhibits phosphatase activity but the role
of phosphorylation at Thr850 is not clear and is evaluated here.
Phosphorylation of both Thr695 and Thr850 by Rho-kinase
inhibited activity of the type 1 phosphatase catalytic subunit.
Rates of phosphorylation of the two sites were similar and eﬃ-
cacy of inhibition following phosphorylation was equivalent for
each site. Phosphorylation of each site on MYPT1 was detected
in A7r5 cells, but Thr850 was preferred by Rho-kinase and
Thr695 was phosphorylated by an unidentiﬁed kinase(s).
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphorylation of the regulatory light chains (LC20) of
myosin II plays an important role in contractile activity in
smooth muscle and many processes in non-muscle cells [1–3].
The level of myosin II phosphorylation is controlled by myosin
light chain kinase (MLCK) [4] and a myosin phosphatase
(MP) [5]. The latter is regulated either by a smooth muscle-spe-
ciﬁc phosphorylation-dependent inhibitory protein (CPI-17)
[6] or, by phosphorylation of the large targeting subunit of
MP (MYPT1) [5,7–9].
Most data on regulation of MP is focused on inhibition of
phosphatase activity and resulting Ca2+-sensitization in
smooth muscle [10]. In this process RhoA and Rho-kinase
(ROK) are implicated [2,11]. Many phosphorylation sites
(14) for ROK were identiﬁed in myosin phosphatase target
subunit (MYPT1) [12], including Thr695, Ser849 and Thr850
(numbering for chicken M133-MYPT1 isoform [13]). At a
lower stoichiometry of phosphorylation Thr695 and Thr850
were the major sites [8]. It was suggested that Thr695 is theAbbreviations: LC20, regulatory myosin light chain; MP, myosin ph-
osphatase; MYPT1, myosin phosphatase target subunit; CPI-17, PKC-
potentiated phosphatase inhibitor protein-17 kDa; ROK, Rho-kinase;
PP1c, type 1 phosphatase catalytic subunit; rPP1c, recombinant cata-
lytic subunit; LPA, lysophosphatidic acid; CL-A, calyculin-A
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doi:10.1016/j.febslet.2005.10.055inhibitory site [7,8] and that phosphorylation of Thr850 did
not inhibit type 1 phosphatase catalytic subunit (PP1c) activity
[8]. While several reports are consistent with a putative regula-
tory function for phosphorylation of Thr695 in smooth muscle
[14–19] and in non-muscle cells [8,20–22] its role as the inhib-
itory site under some conditions has been challenged. Agonist
stimulation of permeabilized smooth muscle ﬁbers caused an
increase in CPI-17 phosphorylation, but did not aﬀect the ba-
sal level of Thr641 (equivalent to Thr695) phosphorylation
[23]. In permeabilized phasic smooth muscles the level of
Thr695 phosphorylation was not changed in response to ago-
nists or GTPcS although phosphorylation of CPI-17 increased
and correlated with force and LC20 phosphorylation. How-
ever, the level of Thr850 phosphorylation increased in parallel
with CPI-17 phosphorylation [24]. Also in permeabilized am-
nion smooth muscle addition of GTPcS increased phosphory-
lation at Thr850 but not at Thr695 [25]. Recently, Wilson et al.
[26] found that the thromboxane A2-induced contraction of rat
caudal artery was accompanied by ROK-dependent phosphor-
ylation of MYPT1 at Thr855 (rat isoform numbering) but did
not increase the basal level of phosphorylation at Thr697. In
non-muscle cells (ﬁbroblast) it was suggested that Thr695
phosphorylation did not play an important role in regulating
rapid changes of contraction downstream of ROK, but
ROK-dependent phosphorylation of Thr850 was involved
[27]. Additional evidence to support a more dynamic role for
Thr850 phosphorylation is evident from higher rates of
dephosphorylation for phosphorylated Thr850 compared to
Thr695 [28].
The possibility that phosphorylation of MYPT1 at Thr850
could be involved in regulation of MP prompted a re-evalua-
tion of the eﬀects of Thr850 phosphorylation. It was found
that phosphorylation of both Thr695 and Thr850 inhibit
PP1c activity and it is suggested that in A7r5 cells the two sites
are targets for diﬀerent kinases.2. Materials and methods
2.1. Materials
Chemicals and vendors were: [c-32P] ATP (Perkin–Elmer Life Sci-
ences); ATP, calyculin-A (Sigma); ATPcS (Calbiochem); 1-O-9-
(Z)-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (non-hydrolyzable
LPA; Avanti Polar Lipids, Inc.); Rho-kinase (ROKa/ROCK II), Y-
27632 (Upstate); nitrocellulose membrane (0.2 lm, Bio-Rad).blished by Elsevier B.V. All rights reserved.
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Full length MYPT1 (chicken M133 sequence [13]) and the Thr695
to Ala mutant (MYPT1T695A) were expressed as glutathione S-trans-
ferase (GST) fusion proteins [8]. The Thr850 to Ala mutant
(MYPT1T850A) and the triple site mutant (Thr695–Ala, Ser694–Ala
and Thr850–Ala (MYPT1AAA)) were generated using the Altered
Sites II in vitro Mutagenesis Systems (Promega). Appropriate prim-
ers were designed and mutants were subcloned into pGEX4T-1
(Amersham Biosciences) expressed in BL-21 (DE3) pLysS E. coli
and puriﬁed [8].
Antibodies speciﬁc for phosphorylated Thr695 (anti P-T695) were: a
monoclonal from Dr. M. Walsh (Univ. of Calgary); and a rabbit poly-
clonal from Upstate. The anti P-T850 rabbit polyclonal was from Up-
state. A monoclonal antibody was raised against the MYPT1 sequence
371–511 using standard techniques [29]. Other protein preparations
were: PP1c from rabbit skeletal muscle [30]; recombinant catalytic sub-
unit (rPP1c) [30]; myosin and LC20 from turkey gizzard [31]; 32P-la-
beled myosin and 32P-labeled LC20 [32].2.3. Phosphorylation assays
Phosphorylation of MYPT1 mutants (1 lM) by ROK (5 mU) was
carried out in 30 mM Tris–HCl (pH 7.5), 85 mM KCl, 5 mM MgCl2,
1 mM EGTA, 1 mM dithiothreitol (DTT) and 0.3 mM [c-32P] ATP
(100–500 cpm/pmol). For most experiments MYPT1 was phosphory-
lated in the absence of PP1c. Some experiments were carried out in
which rPP1c (equimolar to MYPT1) was added before phosphoryla-
tion and both ATP and ATPcS were used. Total assay volumes were
200–500 ll. Aliquots (20 ll) were removed at intervals, spotted onto
P81 Whatman phosphocellulose paper and washed three times in
300 ml 0.5% phosphoric acid, then with acetone. Cerenkov counting
was used to determine 32P incorporation. Alternatively, 30 ll aliquots
were added to an equal volume of SDS–PAGE sample buﬀer, boiled
for 5 min and applied to electrophoresis. To determine eﬀects of phos-
phorylation on phosphatase activity, thiophosphorylation of MYPT1
mutants was carried out for 1 h under similar conditions using ATPcS.
The reactions were diluted with 20 mM Tris–HCl (pH 7.5), 30 mM
KCl, 0.2 mM DTT, 0.4 mg/ml bovine serum albumin and used in
phosphatase assays after addition of native PP1c.2.4. Phosphatase assays
Phosphatase assays were carried out at 30 C using 32P-labeled myo-
sin (3 lM) or 32P-labeled LC20 (5 lM) and rabbit skeletal muscle PP1c
(5–10 mU). Reactions were started by addition of substrates and termi-
nated at 10 min by addition of bovine serum albumin to 6 mg/ml and
trichloroacetic acid to 10%. The precipitated proteins were sedimented
at 15000 · g for 2 min and the radioactivity of the supernatant was
determined by Cerenkov counting.Fig. 1. Phosphorylation of MYPT1 mutants by Rho-kinase. (A) Stoichiom
MYPT1 (j); MYPT1T695A (d); MYPT1T850A(m). Samples (200 ng in each
Western blotting analyses with (B) anti P-T695 antibody and (C) anti P-T850
T850 in the mutants is higher than in wild-type (since in the mutants one si2.5. Cell culture
A7r5 cells were obtained from American Type Culture Collection
and cultured according to suppliers recommendations. Subconﬂuent
cells (70–80% conﬂuence) were washed 3 times with serum-free med-
ium (10 ml for 100 mm dish) and incubated with serum-free medium
for 24 h. The cells were treated with 0.1 lM calyculin-A (CL-A) for
20 min, or 1 lM lysophosphatidic acid (LPA) for 20 min, or 10 lM
Y-27632 for 30 min, or vehicle (phosphate-buﬀered saline containing
0.1% fatty-acid free bovine serum albumin). In some experiments, ser-
um-starved cells were pretreated for 30 min with 10 lM Y-27632
before treatment with LPA or CL-A. Reactions were terminated by
addition of ice-cold trichloroacetic acid to 10%. The precipitated cells
were scraped, sedimented at 15000 · g for 5 min and washed 3 times
with ice-cold acetone and dried. The dried cell powder was lysed in
SDS sample buﬀer and analyzed by Western blotting. The amount
of MYPT1 in the pertinent immunoreactive bands was estimated by
densitometry (C-80, Epi-Illumination UV darkroom, UVP products).
2.6. Other procedures
SDS–PAGE was performed using the conditions of Laemmli [33].
Proteins from mini-gels were blotted onto nitrocellulose membrane
for 1 h at 250 mA. After blocking in 5% non-fat dried milk and
0.05% Tween 20 in TBS, membranes were washed, exposed to primary
antibody overnight at 5 C and subject to peroxidase-coupled second-
ary antibodies using enhanced chemiluminescence reagent (Pierce).
Protein concentrations were determined with the BCA method
(Pierce).3. Results and discussion
3.1. Phosphorylation of MYPT1 and mutants
The two major phosphorylation sites on MYPT1 for ROK
are Thr695 and Thr850 and the initial objective was to compare
the rates of phosphorylation for each site. This was done using
the Thr to Ala point mutants of MYPT1, i.e., MYPT1T695A
and MYPT1T850A. As shown in Fig. 1A the rates of phosphor-
ylation of Thr695 and Thr850 by ROK were identical. Both
were described by the same single exponential plot (data not
shown). The rate of phosphorylation of the wild-type MYPT1
(containing both sites) was slightly faster and predictably the
levels of phosphorylation were higher (Fig. 1A).
To conﬁrm that the expected site in each mutant was phos-
phorylated the phospho-speciﬁc antibodies were used. With
the monoclonal antibody speciﬁc for phosphorylated Thr695etry of phosphorylation of MYPT1 mutants (1 lM) by Rho-kinase.
lane) from phosphorylation assays were subjected to SDS–PAGE and
antibody. At a given time the proportion of phosphorylated Thr695 or
te is eliminated) and this is reﬂected in the Western blots.
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(Fig. 1B). MYPT1T695A was positive with anti P-T850
(Fig. 1C). The wild-type MYPT1 was used as control and
was positive for both antibodies.
In the presence of rPP1c (added before phosphorylation of
MYPT1) and ATP the level of phosphorylation was markedly
reduced, but both Thr695 and Thr850 were phosphorylated.
When ATPcS was used (in place of ATP) the rates of phos-
phorylation of Thr695 and Thr850 were identical (data not
shown). These data indicate that the presence of rPP1c does
not block phosphorylation at either site.
Thus both Thr695 and Thr850 are phosphorylation sites for
ROK and under in vitro conditions the rates of phosphoryla-
tion for each are indistinguishable.
3.2. Eﬀect of phosphorylation at Thr695 and Thr850 on
phosphatase activity
Previously it was suggested that Thr695 on MYPT1 was the
inhibitory site [8]. However, this interpretation is not consis-
tent with some recent data and a major objective of this study
was to re-evaluate the inhibitory eﬀects on PP1c activity of
phosphorylation of MYPT1 at Thr695 and Thr850. Two sub-
strates were used, P-myosin and P-LC20.
The control MYPT1 and 3 mutants, MYPT1T695A,
MYPT1T850A and MYPT1AAA were thiophosphorylated with
ROK and ATPcS (see Section 2). The levels of thiophosphory-
lation were 1.5, 1.4, 1.4 and 1.1 mol thiophosphate/mol protein,
respectively. (For the triplemutant the level of thiophosphoryla-
tion reﬂects the several minor ROK sites [12] that become more
prominent when the major ROK sites are removed). With
P-LC20 the MYPT1AAA mutant had no eﬀect, but inhibition
of PP1c activity was observed for the other thiophosphory-
lated constructs (Fig. 2). The wild-type MYPT1 was most
eﬀective, followed by MYPT1T695A then MYPT1T850A
(Fig. 2A). A similar pattern was observed with P-myosin as
substrate, with the distinction that inhibition of PP1c was
equally eﬀective with MYPT1T695A and MYPT1T850A
(Fig. 2B). Inhibition of PP1c also was observed with phosphor-
ylated (as distinct from thiophosphorylated) MYPT1T695A and
MYPT1T850A (data not shown). Also, the original construct [8]
was assayed with results identical to those given above (data
not shown).P-LC20
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Fig. 2. Eﬀects of thiophosphorylation of MYPT1 and mutants on nativ
MYPT1AAA (¤). (A) 32P-labeled LC20. (B) 32P-labeled myosin. Values areThese results indicate that phosphorylation/thiophosphory-
lation of either Thr695 or Thr850 results in inhibition of native
PP1c activity. With the in situ substrate, P-myosin, the eﬃcacy
of inhibition for each site is similar. These data diﬀer from the
previous suggestion [8] that the only inhibitory site on MYPT1
was Thr695.The reason for the discrepancy between our data
and those of Feng et al. [8] is not clear, although assay condi-
tions are diﬀerent.
3.3. Phosphorylation of Thr695 and Thr850 in A7r5 cells
To investigate the in vivo phosphorylation of MYPT1 the
A7r5 cell line was used. Subconﬂuent cells were treated with
the following agents to assess the role of ROK, namely: Y-
27632, a ROK inhibitor [34]; LPA, an activator of the
RhoA/ROK pathway [35]; and CL-A, an inhibitor of PP1
and PP2A [36].The results are represented by Westerns blots
using the monoclonal anti-MYPT1 antibody, anti P-T695
and anti P-T850 and by the relative intensities of scans for
the two latter antibodies.
For control cells, in the presence and absence of serum, both
Thr695 and Thr850 were phosphorylated (Fig. 3, lanes 1 and
2). The doublet indicates diﬀerent MYPT1 isoforms in these
cells. The levels of Thr695 phosphorylation in the presence
of serum and under serum-starved conditions were
36.1 ± S.E. 4.9 (n = 6) and 47.0 ± S.E. 4.7 (n = 7), respectively.
These values, normalized to MYPT1 content, are not sign-
iﬁcantly diﬀerent. However, it is interesting that serum starva-
tion does not reduce the basal level of Thr695 phosphorylation,
as it does for Thr850. Similar results were obtained using a
second anti P-T695 antibody. Phosphorylation of Thr850
probably reﬂected ROK activity, since the signal was elimi-
nated by Y-27632, but the latter only slightly diminished
phosphorylation of Thr695 in the serum-starved cells
(Fig. 3, lane 3). The PP1 and PP2A phosphatase inhibitor,
CL-A, markedly increased phosphorylation of Thr850, but
had little eﬀect on phosphorylation of Thr695 (Fig. 3, lane
4). Again, in the presence of CL-A only the phosphorylation
of Thr850 was sensitive to inhibition of ROK by Y-27632
(Fig. 3, lane 5). The ROK-independent phosphorylation of
Thr695 was shown initially in serum-starved ﬁbroblasts [8].
Treatment of the serum-starved A7r5 cells with LPA induced
a marked increase in phosphorylation of both Thr695 andP-myosin
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Fig. 3. Phosphorylation of MYPT1 in A7r5 cells. A, Western blots with monoclonal anti-MYPT1 antibody, anti P-T695 and anti P-T850. B,
Relative intensities of anti P-T695 and anti P-T850 signals. The signals were normalized for protein load. Lane 1, control cells plus serum; lane 2,
control serum-starved cells (These cells were used in subsequent treatments); lane 3, 10 lM Y-27632, 30 min; lane 4, 0.1 lM CL-A, 20 min; lane 5,
10 lM Y-27632, 30 min then 0.1 lM CL-A, 20 min; lane 6, 1 lM LPA 20 min; lane 7, 10 lM Y-27632, 30 min then 1 lM LPA 20 min.
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were responsible for phosphorylation at each site since Y-
27632 eliminated the Thr850 signal (i.e., suggesting involve-
ment of ROK) but had only a slight eﬀect on phosphoryla-
tion of Thr695 (Fig. 3, lane 7).
A major point from these results is that phosphorylation of
the two sites appears to be independent and each site is acces-
sible to a diﬀerent kinase(s). Under the conditions used,
Thr850 is a primary site for ROK and is not phosphorylated
in the presence of the ROK inhibitor. It was suggested earlier
[12] that phosphorylation of Thr850 (or, equivalent site in dif-
ferent MYPT1 isoforms) was a useful indicator of ROK activ-
ity in vivo. The kinase(s) responsible for phosphorylation of
Thr695 is not identiﬁed. Phosphorylation of Thr695 is in-
creased by LPA treatment, but since cell signaling via LPA
is complex and involves activation of several pathways [37],
including RhoA-ROK, there could be several kinase candi-
dates for phosphorylation of Thr695. Indeed, many other ki-
nases have been identiﬁed that phosphorylate Thr695,
including MYPT1 kinase; integrin-linked kinase, myotonic
dystrophy protein kinase; p21-activated protein kinase; and
Raf-1 (see reviews [2,5,9]). Under in vitro conditions, the phos-
phorylation of Thr695 and Thr850 by ROK is indistinguish-
able (above results). The mechanism involved in
discrimination of these sites in vivo is unknown and represents
an intriguing challenge. There is also the possibility that in dif-
ferent cells the accessibility of these two sites to distinct kinases
may vary and must be evaluated. An attractive hypothesis is
that the distinction in phosphorylation sites oﬀers a mecha-
nism for integration of diﬀerent signaling pathways converging
on MYPT1. Both sites inhibit PP1c activity and thus diﬀerent
pathways could be involved in regulation of MP activity.
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